BETA-ADRENORECEPTORS GENETIC POLYMORPHISM CONNECTION WITH BETA-BLOKER THERAPY EFFICACY IN PATIENTS WITH CARDIOVASCULAR DISORDERS

At present it is obvious that genetic peculiarities of patients are the major reason for individual differences in pharmacological responses to (?-adrenoblockers. Furthermore ADRB1 gene polymorphism is responsible for the efficiency of (?-adrenoblockers. Thus, a real prospect exists for an individualized approach to administration of (?-adrenoblockers and selection of dosage based on patient’s genotype, which must undoubtedly increase efficiency of the administered therapy. Reviewfocuses on gene polymorphism responsible for (?-adrenoblockers pharmacodynamics and on the clinical significance of the polymorphism detection to individualize drug therapy based on patient’s genotype.